JAMA[journal] 检索结果

761. Bioresorbable vs Metallic Occluders for Transcatheter Atrial Septal Defect Closure: A Randomized Clinical Trial.

作者: Wenbin Ouyang.;Hong Jiang.;Xinxin Yan.;Yimin Hua.;Zhiling Luo.;Shiwei Yang.;Wei Duan.;Tao You.;Jun Jin.;Xianxian Zhao.;Lang Hong.;Xiaofei Jiang.;Shenglin Ge.;Qiuzhe Guo.;Jiahua Pan.;Chuangshi Wang.;Fengwen Zhang.;Shouzheng Wang.;Yunbing Wang.;Xiangbin Pan.
来源: JAMA. 2025年

The permanent metallic occluders used for atrial septal defect (ASD) closure are associated with risks of late complications and may impede access to the left atrium. Bioresorbable occluders have the potential to address these limitations but have yet to be validated in randomized clinical trials.

762. Advisory Committee on Immunization Practices Standards for Assessing Evidence.

作者: Doug Campos-Outcalt.;Jonathan Temte.
来源: JAMA. 2025年334卷23期2063-2064页

763. The Make America Healthy Again Strategy Report.

作者: Peter Lurie.;Lawrence O Gostin.
来源: JAMA. 2025年334卷23期2069-2070页

764. Eltrombopag for Newly Diagnosed Pediatric Immune Thrombocytopenia Requiring Treatment: The PINES Randomized Clinical Trial.

作者: Kristin A Shimano.;Amanda B Grimes.;Shipra Kaicker.;Sanjay J Shah.;Elizabeth Gunn.;Rukhmi V Bhat.;Manpreet Kochhar.;Jennifer A Rothman.;Melissa J Rose.;Michael Briones.;Taizo A Nakano.;Jeffrey D Lebensburger.;Michele P Lambert.;Stephanie A Fritch Lilla.;Rohith Jesudas.;Cathy A Lee-Miller.;Alexis A Thompson.;Stacey Rifkin-Zenenberg.;Suvankar Majumdar.;Shelley E Crary.;Kerry Hege.;James B Ford.;Joshua J Bies.;John Fort.;Tung T Wynn.;Loan Hsieh.;Maritza E Ruiz.;Bogdan Dinu.;Julia M W Wong.;Pei-Chi Kao.;Taylor O Kim.;Staci D Arnold.;Carolyn M Bennett.;Jenny M Despotovic.;Robert J Klaassen.;Ellis J Neufeld.;Cindy E Neunert.;Wendy B London.;Rachael F Grace.
来源: JAMA. 2025年334卷20期1816-1826页

Eltrombopag, a thrombopoietin receptor agonist, is approved by the US Food and Drug Administration for children with chronic immune thrombocytopenia. Efficacy of eltrombopag during the newly diagnosed phase of pediatric immune thrombocytopenia is unknown.

765. A New First-Line Option for Pediatric ITP-Incremental Progress or Paradigm Shift?

作者: Omar Niss.;Russell E Ware.;Charles T Quinn.
来源: JAMA. 2025年334卷20期1802-1803页

766. Poverty, Food Insecurity, and Housing Instability Among US Health Care Workers.

作者: Anthony Zhong.;Chloe Gao.;Donald Szlosek.;Dang Nguyen.;Maelys J Amat.;Russell S Phillips.
来源: JAMA. 2026年335卷1期86-88页

767. Lorundrostat for Uncontrolled Hypertension and Treatment-Resistant Hypertension.

作者: Yu-Hsuan Tai.;Tieh-Cheng Fu.;Ching-Mao Chang.
来源: JAMA. 2025年334卷20期1856页

768. Lorundrostat for Uncontrolled Hypertension and Treatment-Resistant Hypertension-Reply.

作者: Manish Saxena.;David Rodman.
来源: JAMA. 2025年334卷20期1856-1857页

769. Postpartum Hemorrhage.

作者: Scott A Harvey.
来源: JAMA. 2025年334卷22期2031-2032页

770. Audio Highlights: September 26, 2025.

来源: JAMA. 2025年334卷15期e2418962页

771. US Physician Medicare Program Participation and Exit, 2013-2023.

作者: Jonathan Cantor.;Rose Kerber.;Cheryl L Damberg.;Christopher M Whaley.
来源: JAMA. 2025年334卷19期1763-5页

772. A Digital Direct-to-Patient Intervention Shows Promise to Improve Lung Cancer Screening Rates: Multilevel Strategies Remain Essential.

作者: Lauren Kearney.;Lisa Carter-Bawa.;Renda Soylemez Wiener.
来源: JAMA. 2025年334卷20期1799-1801页

773. A Review on Osteoporosis.

作者: Mary L Bouxsein.;Tony M Keaveny.
来源: JAMA. 2025年334卷20期1853-1854页

774. A Direct-to-Patient Digital Health Program for Lung Cancer Screening: Research Summary.

来源: JAMA. 2025年334卷20期e2519250页

775. Recurrent Clostridioides difficile Infections.

作者: Joffrey van Prehn.;Ed J Kuijper.;Erik R Dubberke.
来源: JAMA. 2025年334卷23期2128-2129页

776. Lung Cancer in Nonsmoking Individuals: A Review.

作者: Cian Murphy.;Tej Pandya.;Charles Swanton.;Benjamin J Solomon.
来源: JAMA. 2025年334卷20期1836-1845页

Lung cancer in nonsmoking individuals (defined as people who have smoked fewer than 100 cigarettes in their lifetime) accounts for 15% to 20% of all lung cancer cases worldwide. In the US, the annual incidence of lung cancer in nonsmoking individuals is 14.4 to 20.8 per 100 000 person-years in females and 4.8 to 12.7 per 100 000 person-years in males.

777. A Direct-to-Patient Digital Health Program for Lung Cancer Screening: A Randomized Clinical Trial.

作者: David P Miller.;Anna C Snavely.;Ajay Dharod.;Alison T Brenner.;Elena Wright.;Lindsay Stradtman.;Christina R Bellinger.;Richa Bundy.;Robert J Volk.;Emily Hamburger.;Renée M Ferrari.;Aliza Randazzo.;Daniel S Reuland.
来源: JAMA. 2025年334卷20期1807-1815页

Screening chest computed tomography (CT) scans reduce lung cancer mortality in high-risk individuals, but less than 20% of eligible individuals are screened in the US.

778. A Review on Osteoporosis.

作者: Helene Götz.;Karin Amrein.
来源: JAMA. 2025年334卷20期1854页

779. A Review on Osteoporosis-Reply.

作者: Suzanne N Morin.;William D Leslie.;John T Schousboe.
来源: JAMA. 2025年334卷20期1855-1856页

780. What Is Small Cell Lung Cancer?

作者: Rebecca Voelker.
来源: JAMA. 2025年334卷20期1862页

结果排序

文献格式

出版时间

出版类型

出版语言